Sight Sciences, Inc. SGHT
Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients' lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals ("ECPs"); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $77.4M | $79.9M | $81.1M | $71.3M | $49.0M | $27.6M | — |
| Cost of revenue | $10.7M | $11.6M | $11.9M | $12.4M | $8.6M | $9.2M | — |
| Gross profit | $66.7M | $68.3M | $69.2M | $59.0M | $40.3M | $18.4M | — |
| R&D | $14.6M | $18.0M | $17.6M | $22.9M | $15.6M | $8.9M | — |
| SG&A | $89.2M | $100.8M | $108.9M | $120.1M | $76.2M | $41.7M | — |
| Total operating expenses | $103.8M | $118.8M | $126.4M | $142.9M | $91.8M | $50.6M | — |
| Operating income | -$37.1M | -$50.5M | -$57.3M | -$84.0M | -$51.5M | -$32.2M | — |
| Interest expense | $5.1M | $4.7M | $5.4M | $4.5M | $4.4M | $2.4M | — |
| Pre-tax income | -$38.4M | -$51.3M | -$55.4M | -$86.2M | -$62.8M | -$34.6M | — |
| Income tax | $10.0K | $236.0K | $110.0K | $47.0K | $188.0K | $61.0K | — |
| Net income | -$38.4M | -$51.5M | -$55.5M | -$86.2M | -$63.0M | -$34.7M | — |
| EPS, basic | -0.74 | -1.03 | -1.14 | -1.80 | -2.36 | — | — |
| EPS, diluted | -0.74 | -1.03 | -1.14 | -1.80 | -2.36 | -3.71 | — |
| Shares, diluted (wtd. avg.) | $52.1M | $50.1M | $48.6M | $47.8M | $26.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.0M | $120.4M | $138.1M | $185.0M | $260.7M | $61.5M | $21.2M |
| Receivables | $9.7M | $10.8M | $14.3M | $15.1M | $8.7M | $5.4M | — |
| Inventory | $7.8M | $6.3M | $7.8M | $6.1M | $3.5M | $2.6M | — |
| Total current assets | $112.7M | $139.8M | $162.9M | $209.7M | $277.0M | $70.6M | — |
| Property, plant and equipment | $1.6M | $1.6M | $1.6M | $1.6M | $1.5M | $1.3M | — |
| Total assets | $115.3M | $142.8M | $166.7M | $213.1M | $280.2M | $72.8M | — |
| Accounts payable | $1.3M | $1.7M | $1.7M | $2.7M | $3.4M | $2.2M | — |
| Short-term debt | $0 | $0 | $2.2M | $0 | $0 | $0 | — |
| Total current liabilities | $11.0M | $15.5M | $12.3M | $17.8M | $13.5M | $9.3M | — |
| Long-term debt | $40.3M | $39.4M | $31.7M | $33.3M | $32.7M | $32.0M | — |
| Total liabilities | $51.4M | $55.3M | $46.4M | $53.0M | $48.1M | $44.3M | — |
| Retained earnings | -$384.7M | -$346.3M | -$294.8M | -$239.2M | -$153.0M | -$90.0M | — |
| Total equity | $63.9M | $87.5M | $120.2M | $160.1M | $232.1M | -$88.8M | -$54.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.7M | -$22.4M | -$47.2M | -$76.0M | -$52.5M | -$32.2M | — |
| Depreciation and amortisation | $487.0K | $712.0K | $614.0K | $710.0K | $632.0K | $554.0K | — |
| Stock-based compensation | $13.1M | $17.1M | $14.6M | $13.0M | $5.1M | $497.0K | — |
| Capital expenditure | $224.0K | $385.0K | $791.0K | $970.0K | $813.0K | $953.0K | — |
| Investing cash flow | -$224.0K | -$385.0K | -$791.0K | -$970.0K | -$813.0K | -$953.0K | — |
| Financing cash flow | $1.8M | $5.0M | $1.1M | $1.2M | $252.5M | $73.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-091558.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |